SCHEMBL9812484

SCHEMBL9812484

Clc1ccccc1COc1ccccc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.69
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
MAOB P27338 4/20 0.62
MAOA P21397 1/20 0.62
IDO1 P14902 2/20 0.57
MAPT P10636 2/20 0.54
TP53 P04637 1/20 0.54
GAA P10253 1/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HTT P42858 1/20 0.53
RAD52 P43351 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
LMNA P02545 2/20 0.51
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
PTPN1 P18031 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7170719 0.93 NR4A2 (0.71) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL11849613 0.92 NR4A2 (0.66) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL21762 0.92 NR4A2 (0.66) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL3618405 0.86 MAPT (0.70) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL29001619 0.84 SMN1; SMN2 (0.66) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL13483791 0.84 MAOB (0.64) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL11093923 0.84 MAOB (0.69) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL6408450 0.84 NR4A2 (0.61) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL920476 0.84 NR4A2 (0.57) NR4A2NPC1RAB9AMAOBMAOA
SCHEMBL931875 0.84 PTPRC (0.59) NR4A2NPC1RAB9AMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0451201-A1 PREPARATION OF BIDENTATE LIGANDS EASTMAN KODAK COMPANY (US) 1991-10-16 EP claimed
WO-1990006930-A1 PREPARATION OF BIDENTATE LIGANDS EASTMAN KODAK COMPANY (US) 1990-06-28 WO claimed
EP-0375576-A1 Preparation of bidentate ligands EASTMAN KODAK COMPANY (US) 1990-06-27 EP claimed
EP-4067355-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYME (DUB) INHIBITORS Mission Therapeutics Limited (GB) 2022-10-05 EP disclosed
EP-3423454-B1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-05-25 EP disclosed
US-20220106315-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LTD (GB) 2022-04-07 US disclosed
US-11236092-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors MISSION THERAPEUTICS LIMITED (GB) 2022-02-01 US disclosed
US-20200247803-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2020-08-06 US disclosed
US-10654853-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors MISSION THERAPEUTICS LIMITED (GB) 2020-05-19 US disclosed
US-20190048008-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2019-02-14 US disclosed
EP-1979978-B1 NONAQUEOUS ELECTROLYTE INCLUDING DIPHENYL ETHER AND LITHIUM SECONDARY BATTERY USING THEREOF PANAX ETEC CO LTD (KR) 2016-04-06 EP disclosed
EP-0451201-A1 PREPARATION OF BIDENTATE LIGANDS EASTMAN KODAK COMPANY (US) 1991-10-16 EP disclosed
WO-1990006930-A1 PREPARATION OF BIDENTATE LIGANDS EASTMAN KODAK COMPANY (US) 1990-06-28 WO disclosed
EP-0375576-A1 Preparation of bidentate ligands EASTMAN KODAK COMPANY (US) 1990-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220106315-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS OTUB1, UBE2E1, RCE1 NR4A2 3046/4885NPC1 2745/4885RAB9A 888/4885
US-20200247803-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS OTUB1, UBE2E1, RCE1 NR4A2 3046/4885NPC1 2745/4885RAB9A 888/4885
US-10654853-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors OTUB1, UBE2E1, RCE1 NR4A2 3046/4885NPC1 2745/4885RAB9A 888/4885
US-20190048008-A1 SPIRO-CONDENSED PYRROLIDINE DERIVATIVES AS DEUBIQUITYLATING ENZYMES (DUB) INHIBITORS OTUB1, UBE2E1, RCE1 NR4A2 3046/4885NPC1 2745/4885RAB9A 888/4885
US-11236092-B2 Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors OTUB1, UBE2E1, RCE1 NR4A2 3046/4885NPC1 2745/4885RAB9A 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.